Foci Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 38.0824 million yuan, a year-on-year decrease of 2.54%

According to the Zhitong Finance APP, Foci Pharmaceutical (002644.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 624 million yuan, a year-on-year decrease of 11.92%. The net profit attributable to shareholders of the listed company was 38.0824 million yuan, a year-on-year decrease of 2.54%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 23.809 million yuan, a year-on-year decrease of 5.45%